 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...1314151617181920212223...208209» |
- |||| Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health
New P4 trial: CSAGCD: Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye (clinicaltrials.gov) - Jan 27, 2026
P4, N=60, Not yet recruiting, Sponsor: Baylor College of Medicine
- |||| ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Enrollment open: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy (clinicaltrials.gov) - Jan 26, 2026
P3, N=140, Recruiting, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Not yet recruiting --> Recruiting
- | Biomarker, Clinical, Retrospective data, Review, Journal: The Efficacy and Safety of Four Novel PCSK9 Monoclonal Antibodies in Patients With Hypercholesterolemia: A Systematic Review With Network Meta-Analysis and Trial Sequential Analysis. (Pubmed Central) - Jan 26, 2026
These findings positioned ongericimab 150?mg Q2W as a clinically optimal PCSK9 inhibitor with robust lipid-lowering capacity. The results highlight the potential of next-generation PCSK9 monoclonal antibodies, particularly in East Asian populations, while underscoring the need for large-scale multinational trials to validate ethnic-specific responses.
- | AiRuiKa (camrelizumab) / HLB Bio Group, Focus V (anlotinib) / Advenchen, Sino Biopharm
Biomarker, Review, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Sequential anlotinib and camrelizumab combination therapy achieves exceptional survival in multi-driver mutated, TMB-low/PD-L1-low/MSS pulmonary sarcomatoid carcinoma: case report and literature review. (Pubmed Central) - Jan 26, 2026
This approach resulted in unprecedented survival outcomes: the 72-month overall survival dramatically exceeds the median OS of less than 12 months reported for advanced PSC, and the patient maintained a progression-free survival of over 37 months on combination therapy, surpassing historical PFS benchmarks. This case provides a clinically actionable framework for managing multi-driver mutated, immunoresistant PSC.
- | ketoconazole / Generic mfg., dexamethasone / Generic mfg., AiTan (rivoceranib) / HLB Bio Group
Journal: CYP genetic polymorphism, and CYP3A inducers and inhibitors regulate apatinib metabolism: Consequences for drug exposure and toxicity risks. (Pubmed Central) - Jan 24, 2026
In rats, dexamethasone decreased apatinib exposure by inducing CYP3A expression, while ketoconazole increased exposure without altering CYP3A levels. Both CYP genetic polymorphisms and drug interactions significantly influence apatinib metabolism, highlighting the importance of personalized dosing strategies for optimizing therapy.
- |||||||||| plinabulin (BPI 2358) / BeyondSpring
New P3 trial: Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) (clinicaltrials.gov) - Jan 24, 2026
P3, N=442, Not yet recruiting, Sponsor: BeyondSpring Pharmaceuticals Inc.
- | New P2 trial: Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer (clinicaltrials.gov) - Jan 23, 2026
P2, N=56, Not yet recruiting, Sponsor: Eastern Hepatobiliary Surgery Hospital
- ||||| ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma
New P2 trial: The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia (clinicaltrials.gov) - Jan 23, 2026
P2, N=300, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD (clinicaltrials.gov) - Jan 23, 2026
P2, N=44, Not yet recruiting, Sponsor: Peking University Cancer Hospital & Institute
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma
New trial, Real-world evidence: Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer (clinicaltrials.gov) - Jan 22, 2026
P=N/A, N=300, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- |||| SHR-1501 / Jiangsu Hengrui Pharma
Enrollment open: Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors (clinicaltrials.gov) - Jan 22, 2026
P1/2, N=203, Recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Both CYP genetic polymorphisms and drug interactions significantly influence apatinib metabolism, highlighting the importance of personalized dosing strategies for optimizing therapy. Not yet recruiting --> Recruiting
- |||||||||| AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, HRS-8080 / Jiangsu Hengrui Pharma
New P3 trial: A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy. (clinicaltrials.gov) - Jan 22, 2026
P3, N=912, Not yet recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
- ||| AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
P3 data, Retrospective data, Journal: Efficacy and safety of vunakizumab in moderate-to-severe plaque psoriasis patients with different body mass index: a post hoc analysis based on a phase III trial. (Pubmed Central) - Jan 22, 2026
P3
The incidences of any adverse events and most specific adverse events did not differ among the groups. A lower BMI is associated with a greater treatment response and quality of life in moderate-to-severe plaque psoriasis patients receiving vunakizumab.
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Enrollment open, Circulating tumor DNA: DNADalHR: ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer (clinicaltrials.gov) - Jan 22, 2026
P2, N=393, Recruiting, Sponsor: Peking University People's Hospital
A lower BMI is associated with a greater treatment response and quality of life in moderate-to-severe plaque psoriasis patients receiving vunakizumab. Not yet recruiting --> Recruiting
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Avastin (bevacizumab) / Roche
New P2 trial: MA-CRC-II-016 SHR-1811 (clinicaltrials.gov) - Jan 21, 2026
P2, N=80, Not yet recruiting, Sponsor: Peking Union Medical College Hospital
- || AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
P2 data, Journal, PD(L)-1 Biomarker, Circulating tumor DNA: Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analyses. (Pubmed Central) - Jan 21, 2026
Neoadjuvant camrelizumab plus apatinib provides a potential sustained benefit for patients with resectable stage IIA-IIIB NSCLC. Metabolic response on PET/CT and perioperative ctDNA clearance might be potential biomarkers for predicting survival.
- | recaticimab (SHR-1209) / Jiangsu Hengrui Pharma
Enrollment open: EAST-LDL: Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion (clinicaltrials.gov) - Jan 21, 2026
P3, N=652, Recruiting, Sponsor: Shanghai East Hospital
Metabolic response on PET/CT and perioperative ctDNA clearance might be potential biomarkers for predicting survival. Not yet recruiting --> Recruiting
- | retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P2 trial: A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer (clinicaltrials.gov) - Jan 21, 2026
P2, N=104, Not yet recruiting, Sponsor: Qinglei Gao
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Case Report: A case of lymph node metastatic cancer of unknown primary with elevated alpha-fetoprotein achieving long-term survival. (Pubmed Central) - Jan 21, 2026
Although subsequent immunohistochemistry classified the case into the unfavorable prognostic subgroup, an individualized treatment strategy including three-drug combination chemotherapy based on the clinical suspicion of gastric cancer, targeted therapy with Apatinib, and localized radiotherapy, resulted in a remarkably long overall survival of 58 months...This case demonstrates that for CUP confined to lymph nodes, active and precisely reasoned individualized treatment can significantly improve prognosis, even in cases categorized as having an unfavorable prognosis. Furthermore, it underscores the necessity of immunohistochemistry for the accurate diagnosis of CUP and suggests that promoting precision medicine strategies may improve outcomes for these patients.
- | imrecoxib (BAP 909) / Jiangsu Hengrui Pharma, celecoxib oral / Generic mfg.
Retrospective data, Review, Journal: Comparative efficacy and safety of imrecoxib versus celecoxib: a systematic review and meta-analysis. (Pubmed Central) - Jan 21, 2026
Given the limitations of small sample sizes, short follow-up durations, and incomplete safety reporting, further large-scale, high-quality RCTs are warranted to validate these findings. identifier CRD420251243032.
- |||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date, Trial primary completion date: Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC (clinicaltrials.gov) - Jan 21, 2026
P3, N=550, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
identifier CRD420251243032. Trial completion date: Sep 2022 --> Sep 2026 | Trial primary completion date: Apr 2022 --> Apr 2026
- |||||||||| rivocibart (SHR-1918) / Jiangsu Hengrui Pharma
New P3 trial: A Study of SHR-1918 In Participants With Hypertriglyceridemia (clinicaltrials.gov) - Jan 21, 2026
P3, N=360, Not yet recruiting, Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
- | New P2 trial: A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Jan 21, 2026
P2, N=94, Not yet recruiting, Sponsor: Eastern Hepatobiliary Surgery Hospital
- | ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Enrollment open: Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes (clinicaltrials.gov) - Jan 20, 2026
P3, N=1700, Recruiting, Sponsor: Kailera
Trial completion date: Sep 2022 --> Sep 2026 | Trial primary completion date: Apr 2022 --> Apr 2026 Not yet recruiting --> Recruiting
- ||| AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, CS1002 (ipilimumab biosimilar) / CStone Pharma
Enrollment open: Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom (clinicaltrials.gov) - Jan 20, 2026
P1/2, N=139, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Enrollment open: Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes (clinicaltrials.gov) - Jan 20, 2026
P3, N=1200, Recruiting, Sponsor: Kailera
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Enrollment open: Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes (clinicaltrials.gov) - Jan 20, 2026
P3, N=1800, Recruiting, Sponsor: Kailera
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group, fludarabine IV / Generic mfg.
Journal, PD(L)-1 Biomarker, IO biomarker: Apatinib-Induced STAT1/NK axis activation augments PD-1 inhibitor efficacy in advanced Hepatocellular Carcinoma. (Pubmed Central) - Jan 20, 2026
Furthermore, combination therapy remodeled the tumor microenvironment by reducing CA IX (hypoxia marker), CD31 (angiogenesis marker), and ?-SMA (stromal activation marker) expression (p?<?0.05). Apatinib enhances the efficacy and responsiveness of PD-1 inhibition via the STAT1/NK axis, while the combination therapy remodels the tumor microenvironment to potentiate anti-tumor effects.
- || P2 data, Journal: Triple HER2 Blockade With Trastuzumab, Pertuzumab, and Pyrotinib Versus Dual HER2 Blockade in the Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Randomized, Phase II Study. (Pubmed Central) - Jan 20, 2026
Patients with stage II-III HER2-positive breast cancer were randomized (1:1) to receive TPPy or TP alongside weekly nab-paclitaxel for 12 weeks. The most common grade ?3 adverse events in the TPPy and TP groups were diarrhea (58.1%
- AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
Efficacy of rezvilutamide in preventing the flare phenomenon induced by GnRH agonists in newly diagnosed metastatic hormone-sensitive prostate cancer: An exploratory multicenter randomized controlled trial. (Poster Board No.F20; Level 1, West Hall) - Jan 20, 2026 - Abstract #ASCOGU2026ASCO_GU_327;
P4
The most common grade ?3 adverse events in the TPPy and TP groups were diarrhea (58.1% In treatment-na
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma, remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
Journal: Safety and Efficacy of Remimazolam for General Anesthesia in Elderly Patients Undergoing Transurethral Surgery. (Pubmed Central) - Jan 19, 2026
Remimazolam is both safe and effective for transurethral surgery in elderly patients. However, we need to be mindful of the need for monitoring after extubation and the possibility of a temporary reduction in the quality of recovery.
- | AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker: The triglyceride-glucose index shows promise as a novel prognostic marker for advanced hepatocellular carcinoma. (Pubmed Central) - Jan 19, 2026
We further critically examine the methodological limitations, including the retrospective design, the population-specific TyG cut-off value, and unaddressed metabolic confounders. We highlight the imperative for future research to validate its utility across diverse etiologies and treatment settings, and to unravel the underlying immunometabolic pathways.
- | lapatinib / Generic mfg., Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Retrospective data, Journal, Real-world evidence: Efficacy and safety of pyrotinib-based regimens in patients with HER2-positive stage III/IV breast cancer: a real-world retrospective study in China. (Pubmed Central) - Jan 19, 2026
We highlight the imperative for future research to validate its utility across diverse etiologies and treatment settings, and to unravel the underlying immunometabolic pathways. A subgroups comparison found that significant differences were observed in patients who had not used lapatinib (P
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Oncology, AiRuiKa (camrelizumab) / HLB Bio Group
Retrospective data, Review, Journal: Comparative safety profiles of first-line immunotherapy regimens in advanced esophageal squamous cell carcinoma: a network meta-analysis focusing on toxicity stratification. (Pubmed Central) - Jan 19, 2026
These findings should be integrated with regimen-specific efficacy data, regulatory indications, PD-L1 status, comorbidities, and patient preferences, and are best interpreted as complementary safety evidence rather than stand-alone treatment recommendations. https://www.crd.york.ac.uk/prospero/#myprospero, identifier CRD420251113069.
- || AiRuiKa (camrelizumab) / HLB Bio Group, albumin-bound paclitaxel / Generic mfg.
Clinical, P2 data, Journal: Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment for patients with human epidermal growth factor receptor 2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. (Pubmed Central) - Jan 19, 2026
P2
Randomized controlled clinical trials are required to further demonstrate its efficacy and optimal application scenario. https://clinicaltrials.gov/study/NCT04675866?term=Hou%20Xinfang&rank=1, identifier NCT04675866.
- | trastuzumab envedotin (DP303c) / CSPC Pharma, AiTan (rivoceranib) / HLB Bio Group
Journal, Heterogeneity: Case report: Spatiotemporal HER2 heterogeneity in AFP-producing gastric cancer: navigating long-term survival with molecularly-guided therapy in a refractory case. (Pubmed Central) - Jan 19, 2026
Following progression on first-line FLOT chemotherapy, the 65-year-old male received second-line apatinib plus programmed death-1 (PD-1) inhibitor...Third-line anti-HER2 antibody-drug conjugate (ADC) DP303c rapidly achieved partial response with normalized AFP...Overall survival reached 79 months. This case highlights: 1) efficacy of anti-angiogenic and immunotherapy in AFPGC; 2) necessity of re-biopsy for detecting HER2 heterogeneity; and 3) potent activity of ADCs against HER2-converted metastases, enabling remarkable survival through sequential precision therapy.
- || Tarpeyo (budesonide) / Calliditas, Stada, HR19042 / Jiangsu Hengrui Pharma, Budenofalk (budesonide gastro-resistant) / Dr Falk
PK/PD data, Journal: Comparison of the Pharmacokinetics of Three Budesonide Formulations in Healthy Chinese Subjects. (Pubmed Central) - Jan 19, 2026
In vitro, the dissolution of HR19042 occurred 30 min earlier than that of Nefecon in the intestinal buffer medium. In conclusion, both in vivo and in vitro findings suggest that HR19042 exhibits a faster absorption rate and higher oral bioavailability.
- | zeprumetostat (SHR-2554) / Treeline Biosci
New P2 trial: SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma (clinicaltrials.gov) - Jan 17, 2026
P2, N=30, Not yet recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- |||||||||| HRS-8080 / Jiangsu Hengrui Pharma
New P3 trial: A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer (clinicaltrials.gov) - Jan 16, 2026
P3, N=4800, Not yet recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
- ||| trastuzumab rezetecan SC (SHR-A1811 SC) / Jiangsu Hengrui Pharma
Enrollment open: SHR-A1811(sc)-101: A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor (clinicaltrials.gov) - Jan 16, 2026
P1, N=107, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
In conclusion, both in vivo and in vitro findings suggest that HR19042 exhibits a faster absorption rate and higher oral bioavailability. Not yet recruiting --> Recruiting
- ||| HRS-4642 / Jiangsu Hengrui Pharma
Enrollment open: HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors (clinicaltrials.gov) - Jan 15, 2026
P1/2, N=60, Recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | zeprumetostat (SHR-2554) / Treeline Biosci, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New P2 trial, Platinum sensitive: Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer. (clinicaltrials.gov) - Jan 14, 2026
P2, N=30, Not yet recruiting, Sponsor: Peking University Third Hospital
- | zeprumetostat (SHR-2554) / Treeline Biosci
New P1/2 trial: EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas (clinicaltrials.gov) - Jan 14, 2026
P1/2, N=60, Not yet recruiting, Sponsor: Sun Yat-sen University
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Perjeta (pertuzumab) / Roche
New P2 trial: TAYLOR: Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer (clinicaltrials.gov) - Jan 14, 2026
P2, N=200, Recruiting, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
- ||||||| HR17031 / Jiangsu Hengrui Pharma
Trial completion: A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes (clinicaltrials.gov) - Jan 14, 2026
P3, N=393, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Journal: Trastuzumab Rezetecan: First Approval. (Pubmed Central) - Jan 13, 2026
Active, not recruiting --> Completed In May 2025, it was approved by the National Medical Products Administration of China
- || HR17031 / Jiangsu Hengrui Pharma, long acting basal insulin (INS068) / Jiangsu Hengrui Pharma, noiiglutide (SHR20004) / Jiangsu Hengrui Pharma
PK/PD data, Journal: Pharmacokinetics and safety of HR17031, a fixed-ratio of INS068/Noiiglutide combination, in Chinese patients with hepatic impairment. (Pubmed Central) - Jan 13, 2026
HR17031 demonstrated PK profiles of INS068 and Noiiglutide comparable between subjects with mild or moderate hepatic impairment and those with normal hepatic function, with modest reductions in moderate impairment. The treatment was well tolerated with a favourable safety profile, and no significant differences in C-peptide concentrations were observed across groups.
- |||| AiTan (rivoceranib) / HLB Bio Group, yttrium [90Y] microsphere / China Grand Pharma, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC (clinicaltrials.gov) - Jan 13, 2026
P2, N=120, Recruiting, Sponsor: GrandPharma (China) Co., Ltd.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Circulating tumor DNA: ctDNA in HER2+ EBC Neoadjuvant Treatment (clinicaltrials.gov) - Jan 12, 2026
P2, N=60, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New P2 trial: A Study of Hetrombopag Combined With rhTPO in the Treatment of Cancer Therapy-induced Thrombocytopenia (CTIT) in Solid Tumor Patients. (clinicaltrials.gov) - Jan 12, 2026
P2, N=204, Not yet recruiting, Sponsor: Sun Yat-sen University